Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has revealed that in the Phase 3 trials, Denosumab showed a clinically meaningful, consistent treatment effect across tumor types in the reduction of skeletal related events (SREs), and also prevented clinically relevant increases in pain, compared with Zometa (zoledronic acid).
Subscribe to our email newsletter
Reportedly, Zometa (zoledronic acid) is the current standard of care in the prevention of SREs in patients with advanced malignancies involving bone.
Amgen said that the effect of Denosumab versus Zometa was evaluated in three large, identically designed Phase 3 trials that enrolled patients with bone metastases and breast cancer, prostate cancer or other solid tumors and multiple myeloma.
Hershey Medical Center of the Pennsylvania State University Medicine & Oncology professor Allan Lipton said that the analysis of the largest registration program ever undertaken in bone metastases demonstrates that Denosumab can offer a clinical advance over Zometa in delaying or preventing these bony complications, as well as the pain that frequently results from them.
"These efficacy gains coupled with the convenience of a subcutaneous injection and no need for renal monitoring make denosumab an attractive option for these patients," Lipton said.